The priority review voucher craze appears to be subsiding, at least for now, potentially creating a trickle-down effect for sponsors using the voucher to help attract investors.
Sarepta Therapeutics Inc. announced Feb. 21 that it had sold the voucher it received upon approval of its Duchenne...







